Pharmakotherapie bei Arthroseschmerzen

• Verfasst von: Nees, Timo A. [VerfasserIn]
• Verfasst von: Schiltenwolf, Marcus [VerfasserIn]
• Titel: Pharmakotherapie bei Arthroseschmerzen
• Verf.angabe: T.A. Nees, M. Schiltenwolf
• Jahr: 2019
• Jahr des Originals: 2018
• Umfang: 39 S.
• Fussnoten: Online publiziert: 11. April 2018 ; Gesehen am 05.12.2019
• Titel Quelle: Enthalten in: Der Schmerz
• Ort Quelle: Berlin : Springer, 1987
• Jahr Quelle: 2019
• Band/Heft Quelle: 33(2019), 1, Seite 30-48
• ISSN Quelle: 1432-2129
• DOI: doi:10.1007/s00482-018-0286-6
• Datenträger: Online-Ressource
• Sprache: ger
• Sach-SW: Pain
• Sach-SW: Arthrose
• Sach-SW: Arzneimittel
• Sach-SW: Drugs
• Sach-SW: Intraarticular injection
• Sach-SW: Intraartikuläre Injektion
• Sach-SW: Osteoarthritis
• Sach-SW: Pharmacological therapy
• Sach-SW: Pharmakotherapie
• Sach-SW: Schmerz
• K10plus-PPN: 1677507136

Abstract

Joint pain due to osteoarthritis (OA) is often severe and disabling and affects a large proportion of the aging population impairing daily living and quality of life. Numerous pharmacological treatment approaches are available. Including major OA guidelines this review presents the current evidence of pharmacological therapies in OA-related pain and covers topical, oral and intraarticular treatment approaches. In patients with mild OA topical nonsteroidal antiinflammatory drugs (NSAIDs) can be recommended. Topical capsaicin can be used when other treatments are ineffective or contraindicated. In patients with moderate to severe OA oral NSAIDs are suggested at the lowest effective dose for the shortest possible duration to control symptoms. Importantly, drug-related side effects and gastrointestinal, cardiovascular and renal comorbidities need to be taken into account. In patients with multiple-joint OA and high risk of NSAID-induced adverse events duloxetine can be considered. The evidence of metamizole, symptomatic slow-acting drugs in osteoarthritis and other nutritional supplements in the treatment of OA pain is uncertain and the use of opioids is not routinely recommended. In patients suffering from severe OA-related pain intraarticular injections with glucocorticoids can be suggested to achieve short-term pain relief. Evidence for interventional approaches using hyaluronic acid or platelet-rich plasma is uncertain. Yet, the efficacy of pharmacological therapies in OA-related pain is often inconsistent and severe adverse events might occur. Thus, critical use of the different treatment options considering patient-related comorbidities and nonpharmacological therapies is of major importance.